Clinical Trials Directory

Trials / Completed

CompletedNCT02624271

Diagnosis of Gastric Precancerous Lesions by a Blood Test GastroPanel in Patients With Increased Gastric Cancer Risk

Non Invasive Diagnosis of Gastric Precancerous Lesions by GastroPanel Blood Test in Patients With Increased Gastric Cancer Risk : a French Multicenter Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
2,000 (actual)
Sponsor
Nantes University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Despite the declining incidence, gastric cancer (GC) remains the second leading cause of cancer death worldwide. In France, it is the second digestive cancer with 7,000 new cases per year. It is now well demonstrated that patients with H. pylori infection, atrophic gastritis and intestinal metaplasia, have a high risk of developing GC. It is therefore important to detect these pre-neoplastic lesions at an early stage to improve patients prognosis. Thus, the aim of this project is to investigate the possible screening of gastric precancerous lesions by a blood test (GastroPanel®) in France, in patients with oesophagogastroduodenoscopy (EGD) prescription.

Conditions

Interventions

TypeNameDescription
OTHERblood samples analysisAnalyze blood samples with GastroPanel test to detect gastric precancerous lesions.

Timeline

Start date
2016-08-04
Primary completion
2019-05-09
Completion
2019-05-09
First posted
2015-12-08
Last updated
2023-11-15

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02624271. Inclusion in this directory is not an endorsement.